Close menu

August 29th, 2022 | 12:25 CEST

Biotech stocks - The way it has to go! BioNTech, Defence Therapeutics, Bavarian Nordic

  • Biotechnology
Photo credits:

The pharmaceutical and biotech sectors are synonymous with a gold-rush atmosphere. As in the commodities sector, just one discovery can change everything for companies. The best example is BioNTech. Until the pandemic outbreak, the Company was, at best, a household name to biotech nerds. Today, the Palatinate-based company is on top and paying so many taxes that the treasurers of Mainz could pop the corks. We outline three biotech gems and do the future check. We start with BioNTech.

time to read: 3 minutes | Author: Nico Popp

Table of contents:

    BioNTech: Wave of lawsuits causes irritation

    The Mainz-based company recently announced its intention to come up with a vaccine adapted to Omicron as early as the beginning of September. The vaccine against variant BA.1 could soon be approved. Also in the running is a product developed based on the current Omicron variants BA.4 and BA.5. According to BioNTech, the difference between the two vaccines is not very great. Based on the older Corona subtype, the vaccine is also said to offer good protection against current virus variants. In the future, BioNTech wants to react even faster to new virus variants and counteract them with new vaccines. This is to be helped by an early warning system based on artificial intelligence, which recognizes virus variants "with potential".

    The joy over a new wave of vaccines is nevertheless clouded: On Friday, it became known that main competitor Moderna has filed lawsuits against Pfizer and BioNTech for patent infringements in the development of Corona vaccines. The cases were filed in both the US and Germany. Previously, the Tübingen-based company CureVac had filed a suit against BioNTech. In addition, further lawsuits by other companies are pending. Pfizer and BioNTech announced their intention to defend their patents "vigorously". Although BioNTech's share price gave cause for hope at times, it is now bobbing sideways again. The prospect of legal disputes is likely to deter investors. Caution is advised for this share!

    Defence Therapeutics: 3 approval processes around the fight against cancer

    Like BioNTech more than two years ago, cancer specialist Defence Therapeutics appears current. The Company is planning several Phase 1 trials for cancer vaccines starting next year. Defence Therapeutics is choosing a route in which tumor cells are not only destroyed, but a long-term memory response of the immune system is also to be created. Preparations are currently underway to begin the approval process. Specifically, the Company is working on vaccine candidates against skin and cervical cancer. Defence Therapeutics' central technology is Accum™, its patented antibody-drug conjugate (ADC) platform. This type of drug enhancer can target active ingredients in the cell nucleus, thereby increasing its efficacy. Just a few weeks ago, it was confirmed that the technology, used on its own, is also capable of damaging cancer cells so that they die. The process, known as AccuTOX™, is also to be investigated in greater detail as part of a Phase 1 study.

    Defence Therapeutics plans to launch three Phase 1 studies starting next year. These will serve to test the safety of active substances. After that, the other studies will focus on efficacy and dosage. The share has recently come under pressure again after being in a recovery phase. In the medium term, the Company will likely seek further financing rounds. Nevertheless, investors with foresight should take a detailed look at Defence Therapeutics. Detailed analysis and subsequent updates can be found at Being prepared in this way, investors can react better should the stock pick up speed. Given the various projects and the promising field of application, there is certainly potential.

    Bavarian Nordic: Volatility is part of the game!

    The Bavarian Nordic share shows that even an old donkey can become a racehorse overnight in the pharmaceutical and biotech sector. The German-Danish company has a smallpox vaccine in its portfolio that is also approved against monkeypox. The latter is becoming more widespread around the world. Although monkeypox was initially dismissed as posing little danger, there is high demand for vaccination. Official agencies are also now taking the virus seriously. Bavarian Nordic has received a steady stream of new orders for its vaccine in recent months, which has boosted the share price considerably. However, the share price has been bobbing along for several weeks and recently corrected. The reason for this was positive news from competitor Pfizer, which reported good Phase 3 data for a vaccine against respiratory syncytial virus (RSV). Bavarian Nordic is also working on a RSV vaccine at a similar stage.

    Following dynamic upward movements, such as that of Bavarian Nordic, investors must always expect profit-taking. Even BioNTech is now trading well off its previous highs. This shows that volatility is simply part and parcel of the biotech sector. Investors who adjust their position sizes accordingly and invest anticyclically as soon as they are convinced of a technology can exploit advantages. Defence Therapeutics, which is still comparatively unknown, is a good candidate for a "deep dive" for risk-conscious investors.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...


    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.


    Commented by Stefan Feulner on September 27th, 2022 | 11:45 CEST

    Evotec, Defence Therapeutics, Formycon - Biotech opportunity!

    • Biotechnology

    Due to the stricter monetary policy of the central banks and inflation concerns, the capital-intensive biotech sector is also suffering. The NASDAQ Biotechnology Index has lost almost a quarter of its value since the beginning of the stock market year. In addition, the number of companies trading even below their cash levels is higher than ever. At the same time, as can be seen with vaccine manufacturers, the industry is becoming increasingly important in everyday life. Especially in cancer research, some companies have the opportunity to multiply in the coming years based on their product pipeline.